Regarding the effectiveness of gefitinib within NSCLC patients having an EGFR-mutated status, gefitinib was found to have elevated efficacy levels in salvage therapies within NSCLC patients > 85 years of age, extending PFS by 1.4 months (p = 0.070) [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.